Impact of early relapse after auto-SCT for multiple myeloma. (Q53469257)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Impact of early relapse after auto-SCT for multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M R Litzow

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M A Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M Q Lacy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

F K Buadi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

D Dingli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

S Kumar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

S T Mahmood

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

S R Hayman

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

English

0 references

publication date

30 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

413-420

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18587435%20AND%20SRC:MED&resulttype=core&format=json

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Genetics and cytogenetics of multiple myeloma: a workshop report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Using genomics to identify high-risk myeloma after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

A comparison of allografting with autografting for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Combination chemotherapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Effect of complete response on outcome following autologous stem cell transplantation for myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.180

7 January 2021